Seegene
씨젠 · 096530
Health Care Pharmaceuticals · KOSDAQ
Market cap US$1.2B (₩1.7T)
Overview
Seegene makes diagnostic reagents, chemical test kits used in laboratories to identify the genetic material of disease-causing pathogens from patient samples, a field known as molecular diagnostics.
Its products are supplied to hospitals and testing institutions worldwide, distributed through local subsidiaries and a network of agents spanning over a hundred countries. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company earns the vast majority of its revenue from exports, with overseas sales accounting for nearly all of its total revenue. Its core technology allows a single test tube to simultaneously detect multiple pathogens, and it holds dozens of proprietary patents covering this approach.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$266.2M
- FY2024US$300.2M
- FY2025US$343.6M
Operating profit
- FY2023−US$21.8M
- FY2024−US$11.9M
- FY2025US$25M
Net income
- FY2023US$531.3K
- FY2024−US$14.7M
- FY2025US$35.1M
Key ratios (FY2025)
Why it matters
Seegene has entered a technology-sharing initiative, including a strategic collaboration with Microsoft to apply artificial intelligence to its reagent-development automation platform.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?